Phase i study of sunitinib and irinotecan for patients with recurrent malignant glioma

Phase i study of sunitinib and irinotecan for patients with recurrent malignant glioma

We determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of the oral vascular endothelial growth factor receptor (VEGFR) inhibitor, sunitinib, when administered with irinotecan among recurrent malignant glioma (MG) patients. For each 42-day cycle, sunitinib was administered...

Full description

Saved in:
Bibliographic Details
Main Authors: David A. Reardon, James J. Vredenburgh, April Coan, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, Sith Sathornsumetee, Jeremy N. Rich, James E. Herndon, Henry S. Friedman
Other Authors: Duke University School of Medicine
Format: Article
Published: 2018
Subjects:
Biochemistry, Genetics and Molecular Biology
Medicine
Neuroscience
Online Access:https://repository.li.mahidol.ac.th/handle/123456789/11420
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Mahidol University

Internet

https://repository.li.mahidol.ac.th/handle/123456789/11420

Similar Items